80 related articles for article (PubMed ID: 23343910)
1. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.
Braibant M; Gong EY; Plantier JC; Moreau T; Alessandri E; Simon F; Barin F
AIDS; 2013 May; 27(8):1239-44. PubMed ID: 23343910
[TBL] [Abstract][Full Text] [Related]
2. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
[TBL] [Abstract][Full Text] [Related]
3. Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.
Hoffenberg S; Powell R; Carpov A; Wagner D; Wilson A; Kosakovsky Pond S; Lindsay R; Arendt H; Destefano J; Phogat S; Poignard P; Fling SP; Simek M; Labranche C; Montefiori D; Wrin T; Phung P; Burton D; Koff W; King CR; Parks CL; Caulfield MJ
J Virol; 2013 May; 87(10):5372-83. PubMed ID: 23468492
[TBL] [Abstract][Full Text] [Related]
4. Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies.
Ringe R; Phogat S; Bhattacharya J
Virology; 2012 Apr; 426(1):34-41. PubMed ID: 22314018
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.
Thenin S; Roch E; Samleerat T; Moreau T; Chaillon A; Moreau A; Barin F; Braibant M
J Gen Virol; 2012 Jul; 93(Pt 7):1495-1505. PubMed ID: 22492917
[TBL] [Abstract][Full Text] [Related]
6. Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India.
Makhdoomi MA; Singh D; Nair Pananghat A; Lodha R; Kabra SK; Luthra K
Virology; 2016 Dec; 499():105-113. PubMed ID: 27643887
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
[TBL] [Abstract][Full Text] [Related]
8. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
Donners H; Davis D; Willems B; van der Groen G
J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.
Pancera M; McLellan JS; Wu X; Zhu J; Changela A; Schmidt SD; Yang Y; Zhou T; Phogat S; Mascola JR; Kwong PD
J Virol; 2010 Aug; 84(16):8098-110. PubMed ID: 20538861
[TBL] [Abstract][Full Text] [Related]
10. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
[TBL] [Abstract][Full Text] [Related]
11. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
[TBL] [Abstract][Full Text] [Related]
12. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
Doores KJ; Burton DR
J Virol; 2010 Oct; 84(20):10510-21. PubMed ID: 20686044
[TBL] [Abstract][Full Text] [Related]
13. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.
Ferrantelli F; Kitabwalla M; Rasmussen RA; Cao C; Chou TC; Katinger H; Stiegler G; Cavacini LA; Bai Y; Cotropia J; Ugen KE; Ruprecht RM
J Infect Dis; 2004 Jan; 189(1):71-4. PubMed ID: 14702155
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
[TBL] [Abstract][Full Text] [Related]
15. Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.
Cheedarla N; Sundaramurthi JC; Hemalatha B; Anangi B; Nesakumar M; Ashokkumar M; Vidya Vijayan KK; Tripathy SP; Swaminathan S; Vaniambadi SK; Ramanathan DV; Hanna LE
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):169-184. PubMed ID: 30328700
[TBL] [Abstract][Full Text] [Related]
16. Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner.
Patil S; Choudhary I; Chaudhary NK; Ringe R; Bansal M; Shukla BN; Boliar S; Chakrabarti BK; Bhattacharya J
Virology; 2014 Aug; 462-463():266-72. PubMed ID: 24999839
[TBL] [Abstract][Full Text] [Related]
17. Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.
McCoy LE; Falkowska E; Doores KJ; Le K; Sok D; van Gils MJ; Euler Z; Burger JA; Seaman MS; Sanders RW; Schuitemaker H; Poignard P; Wrin T; Burton DR
PLoS Pathog; 2015 Aug; 11(8):e1005110. PubMed ID: 26267277
[TBL] [Abstract][Full Text] [Related]
18. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
[TBL] [Abstract][Full Text] [Related]
19. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.
Moore PL; Gray ES; Sheward D; Madiga M; Ranchobe N; Lai Z; Honnen WJ; Nonyane M; Tumba N; Hermanus T; Sibeko S; Mlisana K; Abdool Karim SS; Williamson C; Pinter A; Morris L;
J Virol; 2011 Apr; 85(7):3128-41. PubMed ID: 21270156
[TBL] [Abstract][Full Text] [Related]
20. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.
Gavrilyuk J; Ban H; Uehara H; Sirk SJ; Saye-Francisco K; Cuevas A; Zablowsky E; Oza A; Seaman MS; Burton DR; Barbas CF
J Virol; 2013 May; 87(9):4985-93. PubMed ID: 23427154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
